// App-Quantinova.ai

e22027 : A phase II clinical trial of neoadjuvant therapy with zoledronic acid for operable breast cancer.

Researchers

Presenter

  • Yoshie Nakayama

Principal Investigators

  • Shunji Takahashi

  • Yoshinori Ito

Medical Centers

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research, Tokyo, Japan

  • Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Disseminated tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Zoledronic acid

  • Fluorouracil

  • Adrucil injection

  • Epirubicin

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved